Anti-proliferative effects of lichen-derived inhibitors of 5-lipoxygenase on malignant cell-lines and mitogen-stimulated lymphocytes

Several lichen species have been used traditionally as medicinal plants. It has previously been shown that two low-molecular-weight lichen metabolites, lobaric acid isolated from Stereocaulon alpinum Laur. and protolichesterinic acid isolated from Cetraria islandica L. (Ach.), have in-vitro inhibito...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmacy and pharmacology 1998, Vol.50 (1), p.107-115
Hauptverfasser: ÖGMUNDSDOTTIR, H. M, ZOËGA, G. M, GISSURARSON, S. R, INGOLFSDOTTIR, K
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 115
container_issue 1
container_start_page 107
container_title Journal of pharmacy and pharmacology
container_volume 50
creator ÖGMUNDSDOTTIR, H. M
ZOËGA, G. M
GISSURARSON, S. R
INGOLFSDOTTIR, K
description Several lichen species have been used traditionally as medicinal plants. It has previously been shown that two low-molecular-weight lichen metabolites, lobaric acid isolated from Stereocaulon alpinum Laur. and protolichesterinic acid isolated from Cetraria islandica L. (Ach.), have in-vitro inhibitory effects on arachidonate 5-lipoxygenase. We have studied the effects of these compounds on cultured cells from man, including three malignant cell-lines (T-47D and ZR-75-1 from breast carcinomas and K-562 from erythro-leukaemia), as well as normal skin fibroblasts and peripheral blood lymphocytes. Both test substances caused a significant reduction in DNA synthesis, as measured by thymidine uptake, in all three malignant cell-lines; the dose inducing 50% of maximum inhibition (ED50) was between 1.1 and 24.6 microg mL(-1) for protolichesterinic acid and between 14.5 and 44.7 microg mL(-1) for lobaric acid. The breast-cancer cell-lines were more sensitive than K-562. The proliferative response of mitogen-stimulated lymphocytes was inhibited with a mean ED50 of 8.4 microg mL(-1) and 24.5 microg mL(-1) for protolichesterinic acid and lobaric acid, respectively. These concentrations are of the same order of magnitude as the IC50 values in the 5-lipoxygenase assay. Significant cell death (assessed by the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-( 4-sulfophenyl)-2H-tetrazolium) assay and trypan blue exclusion) occurred in the three malignant cell-lines at protolichesterinic acid and lobaric acid concentrations above 20 and 30 microg mL(-1), respectively. In K-562 morphological changes consistent with apoptosis were detected. Up to 38% cell death was observed at 20 microg mL(-1) for protolichesterinic acid and 15 microg mL(-1) for lobaric acid in mitogen-stimulated lymphocytes but unstimulated lymphocytes were clearly less sensitive. In contrast, the DNA synthesis, proliferation and survival of normal skin fibroblasts were not affected at doses up to 20 microg mL(-1) for protolichesterinic acid and 30 microg mL(-1) for lobaric acid. We conclude that the anti-proliferative and cytotoxic effects observed might be related to the 5-lipoxygenase inhibitory activity of protolichesterinic acid and lobaric acid. These results open up the opportunity for future studies of these lichen metabolites with regard to their anti-tumour and anti-inflammatory properties.
doi_str_mv 10.1111/j.2042-7158.1998.tb03312.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79724463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79724463</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-90756987e147a0d14cfcbcaf6de575399a1b3c10a60b568e40cd7eccd4282b153</originalsourceid><addsrcrecordid>eNo9kUuP0zAUhS0EGsrAT0CKEGLn4GecsBuNeEkjsYG15TjXU1eOU2wXtXt-OA4T1RsvvnOufc9B6B0lLa3n46FlRDCsqOxbOgx9W0bCOWXt-RnaXdFztCOEMcyl4i_Rq5wPhBDVdd0NuhkkEULQHfp7F4vHx7QE7yCZ4v9AA86BLblZXBO83UPEE6QKpsbHvR99WdJ_KHHwx-V8eYRoMjRLbGYT_GM0sTQWQqg4Qm5MnJq5mqoM5-LnUzClzgqX-bhf7KVAfo1eOBMyvNnuW_Try-ef99_ww4-v3-_vHrDlgyx4IEp2Q6-ACmXIRIV1drTGdRNIJfkwGDpyS4npyCi7HgSxkwJrJ8F6NlLJb9GHp7l1398nyEXPPq8_NRGWU9ZqUEyIjlfhpyehTUvOCZw-Jj-bdNGU6LUCfdBrznrNWa8V6K0Cfa7mt9srp3GG6WrdMq_8_cZNtia4ZKL1-SpjdTsmCf8Hr5mT3w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79724463</pqid></control><display><type>article</type><title>Anti-proliferative effects of lichen-derived inhibitors of 5-lipoxygenase on malignant cell-lines and mitogen-stimulated lymphocytes</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Wiley Online Library All Journals</source><creator>ÖGMUNDSDOTTIR, H. M ; ZOËGA, G. M ; GISSURARSON, S. R ; INGOLFSDOTTIR, K</creator><creatorcontrib>ÖGMUNDSDOTTIR, H. M ; ZOËGA, G. M ; GISSURARSON, S. R ; INGOLFSDOTTIR, K</creatorcontrib><description>Several lichen species have been used traditionally as medicinal plants. It has previously been shown that two low-molecular-weight lichen metabolites, lobaric acid isolated from Stereocaulon alpinum Laur. and protolichesterinic acid isolated from Cetraria islandica L. (Ach.), have in-vitro inhibitory effects on arachidonate 5-lipoxygenase. We have studied the effects of these compounds on cultured cells from man, including three malignant cell-lines (T-47D and ZR-75-1 from breast carcinomas and K-562 from erythro-leukaemia), as well as normal skin fibroblasts and peripheral blood lymphocytes. Both test substances caused a significant reduction in DNA synthesis, as measured by thymidine uptake, in all three malignant cell-lines; the dose inducing 50% of maximum inhibition (ED50) was between 1.1 and 24.6 microg mL(-1) for protolichesterinic acid and between 14.5 and 44.7 microg mL(-1) for lobaric acid. The breast-cancer cell-lines were more sensitive than K-562. The proliferative response of mitogen-stimulated lymphocytes was inhibited with a mean ED50 of 8.4 microg mL(-1) and 24.5 microg mL(-1) for protolichesterinic acid and lobaric acid, respectively. These concentrations are of the same order of magnitude as the IC50 values in the 5-lipoxygenase assay. Significant cell death (assessed by the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-( 4-sulfophenyl)-2H-tetrazolium) assay and trypan blue exclusion) occurred in the three malignant cell-lines at protolichesterinic acid and lobaric acid concentrations above 20 and 30 microg mL(-1), respectively. In K-562 morphological changes consistent with apoptosis were detected. Up to 38% cell death was observed at 20 microg mL(-1) for protolichesterinic acid and 15 microg mL(-1) for lobaric acid in mitogen-stimulated lymphocytes but unstimulated lymphocytes were clearly less sensitive. In contrast, the DNA synthesis, proliferation and survival of normal skin fibroblasts were not affected at doses up to 20 microg mL(-1) for protolichesterinic acid and 30 microg mL(-1) for lobaric acid. We conclude that the anti-proliferative and cytotoxic effects observed might be related to the 5-lipoxygenase inhibitory activity of protolichesterinic acid and lobaric acid. These results open up the opportunity for future studies of these lichen metabolites with regard to their anti-tumour and anti-inflammatory properties.</description><identifier>ISSN: 0022-3573</identifier><identifier>EISSN: 2042-7158</identifier><identifier>DOI: 10.1111/j.2042-7158.1998.tb03312.x</identifier><identifier>PMID: 9504441</identifier><identifier>CODEN: JPPMAB</identifier><language>eng</language><publisher>Wallingford: Pharmaceutical Press</publisher><subject>4-Butyrolactone - analogs &amp; derivatives ; 4-Butyrolactone - pharmacology ; Antineoplastic agents ; Biological and medical sciences ; Chemotherapy ; Depsides ; Ethanol - pharmacology ; Fibroblasts - drug effects ; Humans ; Lactones - pharmacology ; Lichens ; Lipoxygenase Inhibitors - pharmacology ; Lymphocyte Activation - drug effects ; Lymphocytes - drug effects ; Medical sciences ; Pharmacology. Drug treatments ; Salicylates - pharmacology ; Tumor Cells, Cultured</subject><ispartof>Journal of pharmacy and pharmacology, 1998, Vol.50 (1), p.107-115</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-90756987e147a0d14cfcbcaf6de575399a1b3c10a60b568e40cd7eccd4282b153</citedby><cites>FETCH-LOGICAL-c395t-90756987e147a0d14cfcbcaf6de575399a1b3c10a60b568e40cd7eccd4282b153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2147250$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9504441$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ÖGMUNDSDOTTIR, H. M</creatorcontrib><creatorcontrib>ZOËGA, G. M</creatorcontrib><creatorcontrib>GISSURARSON, S. R</creatorcontrib><creatorcontrib>INGOLFSDOTTIR, K</creatorcontrib><title>Anti-proliferative effects of lichen-derived inhibitors of 5-lipoxygenase on malignant cell-lines and mitogen-stimulated lymphocytes</title><title>Journal of pharmacy and pharmacology</title><addtitle>J Pharm Pharmacol</addtitle><description>Several lichen species have been used traditionally as medicinal plants. It has previously been shown that two low-molecular-weight lichen metabolites, lobaric acid isolated from Stereocaulon alpinum Laur. and protolichesterinic acid isolated from Cetraria islandica L. (Ach.), have in-vitro inhibitory effects on arachidonate 5-lipoxygenase. We have studied the effects of these compounds on cultured cells from man, including three malignant cell-lines (T-47D and ZR-75-1 from breast carcinomas and K-562 from erythro-leukaemia), as well as normal skin fibroblasts and peripheral blood lymphocytes. Both test substances caused a significant reduction in DNA synthesis, as measured by thymidine uptake, in all three malignant cell-lines; the dose inducing 50% of maximum inhibition (ED50) was between 1.1 and 24.6 microg mL(-1) for protolichesterinic acid and between 14.5 and 44.7 microg mL(-1) for lobaric acid. The breast-cancer cell-lines were more sensitive than K-562. The proliferative response of mitogen-stimulated lymphocytes was inhibited with a mean ED50 of 8.4 microg mL(-1) and 24.5 microg mL(-1) for protolichesterinic acid and lobaric acid, respectively. These concentrations are of the same order of magnitude as the IC50 values in the 5-lipoxygenase assay. Significant cell death (assessed by the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-( 4-sulfophenyl)-2H-tetrazolium) assay and trypan blue exclusion) occurred in the three malignant cell-lines at protolichesterinic acid and lobaric acid concentrations above 20 and 30 microg mL(-1), respectively. In K-562 morphological changes consistent with apoptosis were detected. Up to 38% cell death was observed at 20 microg mL(-1) for protolichesterinic acid and 15 microg mL(-1) for lobaric acid in mitogen-stimulated lymphocytes but unstimulated lymphocytes were clearly less sensitive. In contrast, the DNA synthesis, proliferation and survival of normal skin fibroblasts were not affected at doses up to 20 microg mL(-1) for protolichesterinic acid and 30 microg mL(-1) for lobaric acid. We conclude that the anti-proliferative and cytotoxic effects observed might be related to the 5-lipoxygenase inhibitory activity of protolichesterinic acid and lobaric acid. These results open up the opportunity for future studies of these lichen metabolites with regard to their anti-tumour and anti-inflammatory properties.</description><subject>4-Butyrolactone - analogs &amp; derivatives</subject><subject>4-Butyrolactone - pharmacology</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Depsides</subject><subject>Ethanol - pharmacology</subject><subject>Fibroblasts - drug effects</subject><subject>Humans</subject><subject>Lactones - pharmacology</subject><subject>Lichens</subject><subject>Lipoxygenase Inhibitors - pharmacology</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Lymphocytes - drug effects</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Salicylates - pharmacology</subject><subject>Tumor Cells, Cultured</subject><issn>0022-3573</issn><issn>2042-7158</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kUuP0zAUhS0EGsrAT0CKEGLn4GecsBuNeEkjsYG15TjXU1eOU2wXtXt-OA4T1RsvvnOufc9B6B0lLa3n46FlRDCsqOxbOgx9W0bCOWXt-RnaXdFztCOEMcyl4i_Rq5wPhBDVdd0NuhkkEULQHfp7F4vHx7QE7yCZ4v9AA86BLblZXBO83UPEE6QKpsbHvR99WdJ_KHHwx-V8eYRoMjRLbGYT_GM0sTQWQqg4Qm5MnJq5mqoM5-LnUzClzgqX-bhf7KVAfo1eOBMyvNnuW_Try-ef99_ww4-v3-_vHrDlgyx4IEp2Q6-ACmXIRIV1drTGdRNIJfkwGDpyS4npyCi7HgSxkwJrJ8F6NlLJb9GHp7l1398nyEXPPq8_NRGWU9ZqUEyIjlfhpyehTUvOCZw-Jj-bdNGU6LUCfdBrznrNWa8V6K0Cfa7mt9srp3GG6WrdMq_8_cZNtia4ZKL1-SpjdTsmCf8Hr5mT3w</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>ÖGMUNDSDOTTIR, H. M</creator><creator>ZOËGA, G. M</creator><creator>GISSURARSON, S. R</creator><creator>INGOLFSDOTTIR, K</creator><general>Pharmaceutical Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1998</creationdate><title>Anti-proliferative effects of lichen-derived inhibitors of 5-lipoxygenase on malignant cell-lines and mitogen-stimulated lymphocytes</title><author>ÖGMUNDSDOTTIR, H. M ; ZOËGA, G. M ; GISSURARSON, S. R ; INGOLFSDOTTIR, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-90756987e147a0d14cfcbcaf6de575399a1b3c10a60b568e40cd7eccd4282b153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>4-Butyrolactone - analogs &amp; derivatives</topic><topic>4-Butyrolactone - pharmacology</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Depsides</topic><topic>Ethanol - pharmacology</topic><topic>Fibroblasts - drug effects</topic><topic>Humans</topic><topic>Lactones - pharmacology</topic><topic>Lichens</topic><topic>Lipoxygenase Inhibitors - pharmacology</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Lymphocytes - drug effects</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Salicylates - pharmacology</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ÖGMUNDSDOTTIR, H. M</creatorcontrib><creatorcontrib>ZOËGA, G. M</creatorcontrib><creatorcontrib>GISSURARSON, S. R</creatorcontrib><creatorcontrib>INGOLFSDOTTIR, K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmacy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ÖGMUNDSDOTTIR, H. M</au><au>ZOËGA, G. M</au><au>GISSURARSON, S. R</au><au>INGOLFSDOTTIR, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-proliferative effects of lichen-derived inhibitors of 5-lipoxygenase on malignant cell-lines and mitogen-stimulated lymphocytes</atitle><jtitle>Journal of pharmacy and pharmacology</jtitle><addtitle>J Pharm Pharmacol</addtitle><date>1998</date><risdate>1998</risdate><volume>50</volume><issue>1</issue><spage>107</spage><epage>115</epage><pages>107-115</pages><issn>0022-3573</issn><eissn>2042-7158</eissn><coden>JPPMAB</coden><abstract>Several lichen species have been used traditionally as medicinal plants. It has previously been shown that two low-molecular-weight lichen metabolites, lobaric acid isolated from Stereocaulon alpinum Laur. and protolichesterinic acid isolated from Cetraria islandica L. (Ach.), have in-vitro inhibitory effects on arachidonate 5-lipoxygenase. We have studied the effects of these compounds on cultured cells from man, including three malignant cell-lines (T-47D and ZR-75-1 from breast carcinomas and K-562 from erythro-leukaemia), as well as normal skin fibroblasts and peripheral blood lymphocytes. Both test substances caused a significant reduction in DNA synthesis, as measured by thymidine uptake, in all three malignant cell-lines; the dose inducing 50% of maximum inhibition (ED50) was between 1.1 and 24.6 microg mL(-1) for protolichesterinic acid and between 14.5 and 44.7 microg mL(-1) for lobaric acid. The breast-cancer cell-lines were more sensitive than K-562. The proliferative response of mitogen-stimulated lymphocytes was inhibited with a mean ED50 of 8.4 microg mL(-1) and 24.5 microg mL(-1) for protolichesterinic acid and lobaric acid, respectively. These concentrations are of the same order of magnitude as the IC50 values in the 5-lipoxygenase assay. Significant cell death (assessed by the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-( 4-sulfophenyl)-2H-tetrazolium) assay and trypan blue exclusion) occurred in the three malignant cell-lines at protolichesterinic acid and lobaric acid concentrations above 20 and 30 microg mL(-1), respectively. In K-562 morphological changes consistent with apoptosis were detected. Up to 38% cell death was observed at 20 microg mL(-1) for protolichesterinic acid and 15 microg mL(-1) for lobaric acid in mitogen-stimulated lymphocytes but unstimulated lymphocytes were clearly less sensitive. In contrast, the DNA synthesis, proliferation and survival of normal skin fibroblasts were not affected at doses up to 20 microg mL(-1) for protolichesterinic acid and 30 microg mL(-1) for lobaric acid. We conclude that the anti-proliferative and cytotoxic effects observed might be related to the 5-lipoxygenase inhibitory activity of protolichesterinic acid and lobaric acid. These results open up the opportunity for future studies of these lichen metabolites with regard to their anti-tumour and anti-inflammatory properties.</abstract><cop>Wallingford</cop><pub>Pharmaceutical Press</pub><pmid>9504441</pmid><doi>10.1111/j.2042-7158.1998.tb03312.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3573
ispartof Journal of pharmacy and pharmacology, 1998, Vol.50 (1), p.107-115
issn 0022-3573
2042-7158
language eng
recordid cdi_proquest_miscellaneous_79724463
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); Wiley Online Library All Journals
subjects 4-Butyrolactone - analogs & derivatives
4-Butyrolactone - pharmacology
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Depsides
Ethanol - pharmacology
Fibroblasts - drug effects
Humans
Lactones - pharmacology
Lichens
Lipoxygenase Inhibitors - pharmacology
Lymphocyte Activation - drug effects
Lymphocytes - drug effects
Medical sciences
Pharmacology. Drug treatments
Salicylates - pharmacology
Tumor Cells, Cultured
title Anti-proliferative effects of lichen-derived inhibitors of 5-lipoxygenase on malignant cell-lines and mitogen-stimulated lymphocytes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A15%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-proliferative%20effects%20of%20lichen-derived%20inhibitors%20of%205-lipoxygenase%20on%20malignant%20cell-lines%20and%20mitogen-stimulated%20lymphocytes&rft.jtitle=Journal%20of%20pharmacy%20and%20pharmacology&rft.au=%C3%96GMUNDSDOTTIR,%20H.%20M&rft.date=1998&rft.volume=50&rft.issue=1&rft.spage=107&rft.epage=115&rft.pages=107-115&rft.issn=0022-3573&rft.eissn=2042-7158&rft.coden=JPPMAB&rft_id=info:doi/10.1111/j.2042-7158.1998.tb03312.x&rft_dat=%3Cproquest_cross%3E79724463%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79724463&rft_id=info:pmid/9504441&rfr_iscdi=true